Trial record 1 of 1 for:
A PHASE IB STUDY OF COMBINATION ATR (M1774) AND BET INHIBITION (ZEN003694) TO EXPLOIT ARID1A LOSS IN RECURRENT OVARIAN AND ENDOMETRIAL CANCER
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05950464 |
|
Recruitment Status :
Recruiting
First Posted : July 18, 2023
Last Update Posted : April 8, 2024
|
Sponsor:
National Cancer Institute (NCI)
Collaborator:
NRG Oncology
Information provided by (Responsible Party):
National Cancer Institute (NCI)
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 30, 2026 |
| Estimated Study Completion Date : | April 30, 2026 |